Unichem Labs Slapped Rs 1.77 Crore NPPA Notice for Alleged Overpricing of 3 Drugs

Written By :  Susmita Roy
Published On 2025-10-04 14:39 GMT   |   Update On 2025-10-04 14:39 GMT
Advertisement

New Delhi: Unichem Laboratories Limited has received three demand notices from the National Pharmaceutical Pricing Authority (NPPA), alleging overcharging for three of its drugs over various periods between 2013 and 2018. The notices, issued under para 15 of the Drug Price Control Order (DPCO), 2013, carry a total penalty of Rs 1.77 crore.

The demand notices, dated 29th September 2025 and received by the company on 3rd October 2025, cite alleged overpricing for the following periods: July 2013 to November 2018, February 2016 to November 2018 and January 2016 to November 2018.

Advertisement

It is noteworthy that Unichem had sold its domestic formulation business in December 2017, which partially overlaps with the alleged period of violation.

Despite the notices, the company has assessed that the penalties are not expected to have any material impact on its financials, operations, or other business activities. Unichem Laboratories is reportedly evaluating legal options to address the NPPA’s notices.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, to the BSE and NSE, where the company’s shares are listed under the script codes 506690 (BSE) and UNICHEMLAB (NSE).

Pradeep Bhandari, Head – Legal & Company Secretary of Unichem Laboratories, confirmed that the company will act in accordance with the applicable legal framework.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News